Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2024-06-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
关于与苏州艾博生物科技有限公司终止新型冠状病毒mRNA疫苗和带状疱疹mRNA疫苗的技术开发合作并签署《终止协议》的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the termination of a technical development cooperation agreement with another company. It details the board meeting resolution, the background of the cooperation, the parties involved, the main content of the termination agreement, authorization to management, and the impact on the company. There are no financial statements, no quarterly or annual financial results, no audit information, no voting results, no executive changes, no merger or acquisition details, and no regulatory certifications. The document is a formal announcement of a corporate event related to business cooperation termination, which is a regulatory announcement. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or M&A filings. It is a typical regulatory filing announcing a corporate event that does not fall into other specific categories.
2024-06-25 Chinese
关于终止与苏州艾博生物科技有限公司合作开发的新型冠状病毒mRNA疫苗临床试验的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the termination of a clinical trial collaboration for a COVID-19 mRNA vaccine. It details the decision made by the company's board and management, the background of the clinical trial, and the company's future plans related to the technology platform. There are no financial statements, no detailed financial performance data, no earnings highlights, no voting results, no regulatory certifications, and no mention of a report being attached or published. The content is an official company announcement about a business decision affecting ongoing research and development projects. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance-related disclosures that do not fit other specific categories.
2024-06-25 Chinese
关于公司人力资源总监辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of the company's Human Resources Director. It details the resignation date, the director's shareholding, and commitments related to shareholding post-resignation. There is no financial data, no mention of financial results, no regulatory filings about financial performance, and no mention of report publication. The content focuses on management change, specifically a senior management personnel change. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2024-06-21 Chinese
关于终止重组新型冠状病毒疫苗（CHO细胞）及重组新型冠状病毒变异株疫苗（CHO细胞）临床试验的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Yunnan Watson Biotechnology Co., Ltd. regarding the termination of clinical trials for two COVID-19 vaccines. It includes details about the decision made by the company's board, the background of the vaccine development, reasons for termination, and the expected impact on the company. The document is short (1158 characters) and serves as an official notice to investors and the public about a specific corporate action related to clinical trial termination. It does not contain financial statements, detailed financial analysis, or regulatory certifications. It is not a full report but an announcement of a corporate event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-06-17 Chinese
关于公司收到发明专利证书的公告
Regulatory Filings Classification · 100% confidence The document is a short announcement (763 characters) from a company about receiving an invention patent certificate. It contains no financial data, no mention of financial results, no regulatory filings related to financial performance, no management changes, no voting results, no capital changes, and no legal proceedings. It is a typical corporate announcement about intellectual property rights. It does not fit into any financial report categories such as Annual Report, Interim Report, Earnings Release, or others. It is not a report publication announcement since it is not announcing the release of a report but rather a patent certificate. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other categories.
2024-06-12 Chinese
关于公司及子公司收到两项发明专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement about receiving two invention patent certificates from the Chinese National Intellectual Property Administration. It details the patent names, numbers, application dates, and descriptions. There is no financial data, no mention of financial results, no regulatory filings, no meeting materials, no voting results, no management changes, no legal proceedings, no capital changes, and no other financial or governance report content. The document is a regulatory announcement about intellectual property rights, which does not fit into any specific financial report category. Therefore, it falls under the fallback category of Regulatory Filings (RNS). The document length is short (1106 characters), and it is a standalone announcement, not a report publication announcement or certification. Hence, the classification is RNS with high confidence.
2024-05-24 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.